IMCR forecasts $0.02 EPS and $110.37M revenue for Q2 2026, reflecting double-digit year-over-year growth.
Immunocore will report Q2 2026 earnings on August 6 before the market opens. Analysts expect earnings per share of $0.02, up 110.0% year-over-year, and revenue of $110.37M, a 12.6% increase from the same period last year.
Over the past three months, EPS estimates have seen eight upward revisions and one downward, while revenue estimates have had four upward and three downward adjustments. The company’s performance outlook remains closely watched amid sector volatility.
No immediate market reaction details were provided ahead of the release.